Why Structure Therapeutics (GPCR) Is Up 23.2% After Aleniglipron Milestone And $748 Million Raise – And What's Next

Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...
Seeking Alpha

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...